ERBB2 and ductal breast carcinoma in situ: In a series of 266 DCIS patients with ipsilateral recurrences, invasive recurrences were more often preceded by ER-positive, HER2-negative DCIS, whereas in situ recurrences were more often preceded by ER-negative, HER2-positive DCIS [37].